Pacific Biosciences Of California (PACB) EBT (2010 - 2026)

Pacific Biosciences Of California's EBT history runs 17 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• On a quarterly basis, EBT rose 98.1% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$127.8 million, a 80.57% increase from a year earlier, with the FY2025 full-year figure at -$546.1 million, down 76.41% from the prior year.
• EBT rose to -$8.1 million in Q1 2026 per PACB's latest filing, from -$40.2 million in the prior quarter.
• Across five years, EBT topped out at $2.7 million in Q4 2024 and bottomed at -$426.4 million in Q1 2025.
• The 5-year median for EBT is -$77.0 million (2022), against an average of -$88.0 million.
• Across the five-year window, EBT surged 103.25% in 2024 and plunged 1594.94% in 2025, its largest moves.
• Year by year, EBT stood at -$84.4 million in 2022, then gained by 1.95% to -$82.7 million in 2023, then jumped by 103.25% to $2.7 million in 2024, then tumbled by 1594.94% to -$40.2 million in 2025, then soared by 79.86% to -$8.1 million in 2026.
• Per Business Quant, the three latest PACB EBT figures stand at -$8.1 million (Q1 2026), -$40.2 million (Q4 2025), and -$37.6 million (Q3 2025).